Comparison of RAEB-T with other MDS
| . | RAEB-T median (range) . | Other MDS . | P . |
|---|---|---|---|
| Caspase 3 activity* | 7.87 (0-26) | 9.25 (0-38.49) | NS |
| PCNA* | 3.35 (.98-7.88) | 3.08 (.73-12.21) | NS |
| Age | 61.5 (19-84) | 65 (21-82) | NS |
| AHD | 1 (0-1000) | 3 (0-96) | .01 |
| B2M | 2.4 (1-8.10) | 2.5 (.8-5.8) | NS |
| PLT | 38.5 (1-471) | 41 (2-184.0) | NS |
| HGB | 7.7 (3.6-15.1) | 7.8 (4.4-12.4) | NS |
| VEGF* | 4 (1-15) | 6.5 (2.5-10.3) | NS |
| BM cellularity | 65 (5-100) | 50 (5-100) | .005 |
| Poor cytogenetics (−5,−7,11q23,+8) | 50% | 53% | NS |
| Therapy-related | 27% | 35% | NS |
| . | RAEB-T median (range) . | Other MDS . | P . |
|---|---|---|---|
| Caspase 3 activity* | 7.87 (0-26) | 9.25 (0-38.49) | NS |
| PCNA* | 3.35 (.98-7.88) | 3.08 (.73-12.21) | NS |
| Age | 61.5 (19-84) | 65 (21-82) | NS |
| AHD | 1 (0-1000) | 3 (0-96) | .01 |
| B2M | 2.4 (1-8.10) | 2.5 (.8-5.8) | NS |
| PLT | 38.5 (1-471) | 41 (2-184.0) | NS |
| HGB | 7.7 (3.6-15.1) | 7.8 (4.4-12.4) | NS |
| VEGF* | 4 (1-15) | 6.5 (2.5-10.3) | NS |
| BM cellularity | 65 (5-100) | 50 (5-100) | .005 |
| Poor cytogenetics (−5,−7,11q23,+8) | 50% | 53% | NS |
| Therapy-related | 27% | 35% | NS |
The values of caspase 3 activity, PCNA, and VEGF represent folds of the mean level observed in 12 normal control bone marrows, which is assigned a value of 1.